Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 1
2007 2
2008 3
2009 2
2011 2
2012 1
2013 3
2014 4
2015 8
2016 4
2017 4
2018 4
2019 5
2020 7
2021 7
2022 7
2023 6
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean junpeng zhuang[Author] (19 results)?
Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms.
Bao M, Zhang M, Shi H, Liu X, Duan M, Zhuang J, Du X, Qin L, Hui W, Liang R, Wang M, Chen Y, Li D, Yang W, Tang G, Zhang W, Kuang X, Su W, Han Y, Chen L, Xu J, Liu Z, Huang J, Zhao C, Tong H, Hu J, Chen C, Chen X, Xiao Z, Jiang Q. Bao M, et al. Among authors: zhuang j. Acta Haematol. 2023;146(4):293-306. doi: 10.1159/000529750. Epub 2023 Feb 22. Acta Haematol. 2023. PMID: 36812897
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial.
Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, Jiang Q, Wang X, Huang J, Zhu H, Yang L, Du X, Li F, Xia R, Zhang F, Hu J, Li Y, Hu Y, Liu J, Jin C, Sun K, Zhou Z, Wu L, Yu W, Jin J. Zhang Y, et al. Among authors: zhuang j. Am J Hematol. 2022 Dec;97(12):1510-1519. doi: 10.1002/ajh.26709. Epub 2022 Oct 4. Am J Hematol. 2022. PMID: 36054786 Free PMC article. Clinical Trial.
The pathogenesis of the bone disease of multiple myeloma.
Edwards CM, Zhuang J, Mundy GR. Edwards CM, et al. Among authors: zhuang j. Bone. 2008 Jun;42(6):1007-13. doi: 10.1016/j.bone.2008.01.027. Epub 2008 Feb 21. Bone. 2008. PMID: 18406675 Free PMC article. Review.
Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.
Shi D, Shi H, Liu X, Duan M, Zhuang J, Du X, Qin L, Hui W, Liang R, Wang M, Chen Y, Li D, Yang W, Tang G, Zhang W, Kuang X, Su W, Han Y, Chen L, Xu J, Liu Z, Huang J, Zhao C, Tong H, Hu J, Chen C, Chen X, Xiao Z, Jiang Q. Shi D, et al. Among authors: zhuang j. Leuk Lymphoma. 2021 Nov;62(11):2703-2715. doi: 10.1080/10428194.2021.1933481. Epub 2021 Jun 8. Leuk Lymphoma. 2021. PMID: 34098836
[Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer].
Ni J, Huang M, Zhang L, Wu N, Bai C, Chen L, Liang J, Liu Q, Wang J, Wu Y, Zhang F, Zhang S, Chen C, Chen J, Fang W, Gao S, Hu J, Jiang T, Li S, Li H, Liao Y, Liu Y, Liu D, Liu H, Liu J, Liu L, Wang M, Wang C, Yang F, Yang Y, Zhang L, Zhi X, Zhong W, Guan Y, Guo X, He C, Li S, Li Y, Liang N, Lu F, Lv C, Lv W, Si X, Tan F, Wang H, Wang J, Yan S, Yang H, Zhu H, Zhuang J, Zhuo M. Ni J, et al. Among authors: zhuang j. Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):141-160. doi: 10.3779/j.issn.1009-3419.2021.101.06. Zhongguo Fei Ai Za Zhi. 2021. PMID: 33819964 Free PMC article. Chinese.
Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China.
Zhuang Z, Tian Y, Shi L, Zou D, Feng R, Tian WW, Yu H, Dong F, Liao A, Ma Y, Liu Q, Liu S, Jing H, Fu R, Ma LM, Liu H, Sun W, Bao L, Wu Y, Chen W, Zhuang J. Zhuang Z, et al. Among authors: zhuang j. Front Oncol. 2023 Apr 20;13:1028571. doi: 10.3389/fonc.2023.1028571. eCollection 2023. Front Oncol. 2023. PMID: 37152063 Free PMC article.
Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study.
Bao L, Wang YT, Liu P, Lu MQ, Zhuang JL, Zhang M, Xia ZJ, Li ZL, Yang Y, Yan ZY, Jing HM, Dong F, Chen WM, Wu Y, Zhou HB, Fu R, Gong YP, Huang WR, Zhang YQ. Bao L, et al. EClinicalMedicine. 2024 Jan 25;68:102431. doi: 10.1016/j.eclinm.2024.102431. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38318126 Free PMC article.
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, Jiang Q, Wang X, Huang J, Zhu H, Yang L, Du X, Li F, Xia R, Zhang F, Hu J, Li Y, Hu Y, Liu J, Jin C, Sun K, Zhou Z, Wu L, Yin H, Suo S, Yu W, Jin J. Zhang Y, et al. Among authors: zhuang j. Am J Hematol. 2024 Apr;99(4):774-779. doi: 10.1002/ajh.27245. Epub 2024 Feb 11. Am J Hematol. 2024. PMID: 38343062 Clinical Trial.
72 results